Anionic Polymer Compositions Blocking Aβ-Oligomer PrPC Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for amyloid-related disorders, such as Alzheimer's disease, are inadequate, and there is a need for more potent inhibitors of the Aβ-oligomer/PrPC interaction to prevent neurodegeneration.
Innovation Solution
Anionic polymers, such as dextran sulfate sodium and pentosan polysulfate, are used to inhibit the binding of Aβ-oligomers to cellular prion protein, blocking the interaction and preventing the progression of amyloid-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic options are used for amyloid-related disorders, then treatment is provided, but the treatment efficacy is inadequate
Solution Approach 1:
The patent changes the chemical structure parameters of existing anionic polymers (dextran sulfate, pentosan polysulfate) to create modified versions with enhanced inhibitory activity against Aβ-oligomer/PrPC interaction. This involves modifying molecular weight, sulfation degree, and polymer composition to optimize therapeutic efficacy while maintaining the fundamental mechanism of action.
Solution Approach 2:
The patent develops composite polymer formulations combining different anionic polymer components with complementary properties. These composite materials synergistically enhance the inhibition of Aβ-oligomer binding to PrPC, providing superior treatment efficacy compared to single polymer components alone.
2Reliability
If anionic polymers are used to inhibit Aβ-oligomer/PrPC interaction, then binding is blocked, but more potent inhibitors are still needed
Solution Approach 1:
The patent introduces local modifications to specific regions of the anionic polymer molecules, particularly at the binding interface with Aβ-oligomers. This involves adding specific functional groups or modifying local charge distribution to enhance affinity and selectivity for the Aβ-oligomer/PrPC complex, thereby increasing therapeutic potency without requiring uniform changes throughout the entire polymer structure.
Solution Approach 2:
The patent designs anionic polymers with dynamic conformational flexibility that allows them to adapt their structure upon binding to Aβ-oligomers. This dynamic behavior enables the polymers to optimize their binding interface in real-time, enhancing inhibition efficacy. The polymers can undergo conformational changes to maximize interaction with the target complex, providing more potent and adaptable inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anionic polymers effectively block Aβ-oligomer/PrPC interaction, showing therapeutic potential in treating and preventing conditions like Alzheimer's disease by restoring synaptic plasticity and improving memory function in animal models.
Implementation Method 1
Cellular Prion Protein (PrPC) was identified as an Aβ-oligomer (ADDL) receptor by expression cloning... Aβ-oligomers bind PrPC with nanomolar affinity... anionic polymers... inhibit the binding of Aβ-oligomer to cellular prion protein
Data Source
AI summary
The disclosure provides polymeric compounds that inhibit binding of an amyloid-β-oligomer to cellular prior protein, methods for identifying such compounds, and their therapeutic use. In particular, the present disclosure provides a collection of anionic polymers and methods of using these compounds to treat amyloid-related disorders, e.g., Alzheimer's disease.